Health and Healthcare

MannKind : MNKD

All MannKind Articles

305 Articles

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Chris Lange | Aug 27, 2014 at 10:25 AM EDT

Rising Short Interest in Biotech Stocks

Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.

Jon C. Ogg | Aug 13, 2014 at 9:53 AM EDT

What the Market Is Telling MannKind (Updated)

Jon OggMannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week’s news that Sanofi (NYSE: SNY)…

Jon C. Ogg | Aug 11, 2014 at 9:11 AM EDT

MannKind Secures Future of Afrezza in Major Sanofi Deal

ThinkstockMannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of…

Jon C. Ogg | Jul 5, 2014 at 9:20 AM EDT

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

ThinkstockStocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors…

Jon C. Ogg | Jul 2, 2014 at 11:55 AM EDT

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

24/7 Wall St. ran a poll for investors this week on where MannKind shares would go into 2015, and the…

Jon C. Ogg | Jul 1, 2014 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms on Tuesday, July 1. They include Amicus…

Jon C. Ogg | Jun 30, 2014 at 2:30 PM EDT

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

ThinkstockMannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug…

Paul Ausick | Jun 30, 2014 at 10:30 AM EDT

Vindication for MannKind on FDA Approval

After markets closed last Friday, MannKind announced that the FDA had approved Afrezza, a rapid-acting, inhaled insulin powder that improves…

Paul Ausick | Jun 27, 2014 at 4:47 PM EDT

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

ThinkstockThe U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin…

Jon C. Ogg | Jun 14, 2014 at 11:10 AM EDT

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

ThinkstockStocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close…

Jon C. Ogg | Jun 14, 2014 at 9:20 AM EDT

The MannKind Lifeline Lights Up

MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for…

Jon C. Ogg | Jun 13, 2014 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Friday, June 13, 2014. They include Alcoa, Intel,…

Jon C. Ogg | Jun 11, 2014 at 6:50 AM EDT

Short Sellers Remain Vigilant Against Top Biotech Stocks

ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger…

Jon C. Ogg | May 17, 2014 at 9:10 AM EDT

Twelve Analyst Stocks to Buy Under $10 for Big Upside

ThinkstockStocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7…

1 … 15 16 17 18 19 … 21

MannKind : MNKD

All MannKind Articles

Short Sellers Remain Vigilant Against Biotechs

Rising Short Interest in Biotech Stocks

What the Market Is Telling MannKind (Updated)

MannKind Secures Future of Afrezza in Major Sanofi Deal

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

Vindication for MannKind on FDA Approval

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

The MannKind Lifeline Lights Up

Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More

Short Sellers Remain Vigilant Against Top Biotech Stocks

Twelve Analyst Stocks to Buy Under $10 for Big Upside

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

Fed’s Rate Freeze Could Sting for Social Security Recipients

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

MannKind : MNKD

All MannKind Articles

Short Sellers Remain Vigilant Against Biotechs

Rising Short Interest in Biotech Stocks

What the Market Is Telling MannKind (Updated)

MannKind Secures Future of Afrezza in Major Sanofi Deal

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

Vindication for MannKind on FDA Approval

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

The MannKind Lifeline Lights Up

Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More

Short Sellers Remain Vigilant Against Top Biotech Stocks

Twelve Analyst Stocks to Buy Under $10 for Big Upside

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

Fed’s Rate Freeze Could Sting for Social Security Recipients